Cargando…

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis

INTRODUCTION: The comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) has not been systematically assessed using recent phase 3 data. This network meta-analysis assesses the comparative efficacy of targeted systemic therapies without the addition of topi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silverberg, Jonathan I., Hong, H. Chih-ho, Thyssen, Jacob P., Calimlim, Brian M., Joshi, Avani, Teixeira, Henrique D., Collins, Eric B., Crowell, Marjorie M., Johnson, Scott J., Armstrong, April W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110624/ https://www.ncbi.nlm.nih.gov/pubmed/35435637 http://dx.doi.org/10.1007/s13555-022-00721-1

Ejemplares similares

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)

Addressing topical corticosteroid phobia in atopic dermatitis: The role of the pharmacist
por: Ladda, Matthew, et al.
Publicado: (2021)

Cortisol Homeostasis in the Epidermis is Influenced by Topical Corticosteroids in Patients with Atopic Dermatitis
por: Fukaya, Mototsugu
Publicado: (2017)

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

The long‐term safety of topical corticosteroids in atopic dermatitis: A systematic review
por: Harvey, Jane, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period
por: Fukaya, Mototsugu, et al.
Publicado: (2016)

Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series
por: Arnold, Kathryn A., et al.
Publicado: (2018)

Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey
por: El Hachem, Maya, et al.
Publicado: (2017)

Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis—a systematic review
por: Shetty, Kshitya, et al.
Publicado: (2021)

Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis
por: McAleer, M. A., et al.
Publicado: (2021)

Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
por: Silverberg, J.I., et al.
Publicado: (2021)

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Topical tacrolimus as treatment of atopic dermatitis
por: Furue, Masutaka, et al.
Publicado: (2009)

Topical steroid addiction in atopic dermatitis
por: Fukaya, Mototsugu, et al.
Publicado: (2014)

Topical Therapy in Atopic Dermatitis in Children
por: Sathishkumar, Dharshini, et al.
Publicado: (2016)

Tolerability of Topical Treatments for Atopic Dermatitis
por: Draelos, Zoe D., et al.
Publicado: (2019)

What’s New in Topicals for Atopic Dermatitis?
por: Kleinman, Elana, et al.
Publicado: (2022)

TOPICOP©: A New Scale Evaluating Topical Corticosteroid Phobia among Atopic Dermatitis Outpatients and Their Parents
por: Moret, Leïla, et al.
Publicado: (2013)

A labelling system improves parental comfort and willingness to use topical corticosteroids for paediatric atopic dermatitis
por: Wilson, F., et al.
Publicado: (2020)

Topical Corticosteroid Phobia Among Parents of Children with Atopic Dermatitis (Eczema)- A Cross-Sectional Study
por: Albogami, Maha Fayez, et al.
Publicado: (2023)

Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis
por: Fröschl, Barbara, et al.
Publicado: (2007)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis
por: Siegfried, Elaine C., et al.
Publicado: (2016)

Associations between atopic dermatitis and other disorders
por: Silverberg, Jonathan I.
Publicado: (2018)

Phenotypic differences of atopic dermatitis stratified by age
por: Chatrath, Sheena, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials
por: Paller, Amy S., et al.
Publicado: (2023)

Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma
por: Andersen, Yuki M.F., et al.
Publicado: (2017)

Process utilities for topical treatment in atopic dermatitis
por: Retzler, Jenny, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0uj0fp8l1rt04rjsq5ta35a38u